Government: unconvinced about safety & efficacy of Nevirapine
“Public pressure for a cure and for quick solutions, while understandable, could contribute to hasty decisions to assuage the sentiments of the public with extremely negative consequences.” – Affidavit from Dr Ayanda Ntsaluba, Director General of Health.
Government argues that TAC is trying to get the courts to change the policy embarked on by the health minister. It submits that it is not the role of the courts to make policy decisions.
Government also argues, principally through an affidavit by Ntsaluba, that it is not violating the Constitution. It states that it has the duty to balance a number of complicated factors, including fiscal and operational issues, before taking action.
Ntsaluba says TAC’s proposed solutions are impractical. They “ignore the vital infrastructural and operational considerations which accompany treatment with nevirapine, such as voluntary counselling and testing and the monitoring and evaluation of the mother and child to ensure effectiveness and to alert to the development of resistant viral strains which may lead to other public health crises”.
Government argues that it is justified in introducing a mother-to-child transmission (MTCT) programme through its 18-site “Research and Training Programme” as not enough is known about various aspects of the use of Nevirapine.
The Medicines Control Council (MCC) registered nevirapine, based only on the Ugandan study of the efficacy of the drug in preventing MTCT, notes government. The MCC regarded the South African (SAINT) study of the drug’s efficacy in MTCT, (on which TAC’s case relies in part) to be inconclusive on the question of the efficacy of Nevirapine in reducing the risk of MTCT.
There is not enough research on whether a child who had nevirapine at birth will be HIV-negative at the age of two, as HIV can be transmitted by breastfeeding. The government papers note that a Ugandan study evaluating the efficacy of nevirapine beyond 18 months showed that nevirapine would only save 10 out of every 100 babies born to HIV-positive mothers.
The Research and Training Programme aims to discover what it would take to sustain the benefits of using nevirapine at birth.
Simply allowing doctors in public hospitals the right to dispense nevirapine at their own discretion is not a solution, adds Ntsaluba. Hospitals may lack services such as counselling services and the supply of breast milk substitutes. In addition, if doctors could prescribe whatever drugs they wanted, this could have serious budgetary implcations.
His affidavit is supported by affidavits from eight provincial heads of health; Dr Nono Simelela (Manager of the National AIDS Programme); Dr Lindiwe Makubalo (Chief Director for Health Surveillance, Monitoring and Evaluation) and the Medicines Control Council.
Author
Kerry Cullinan is the Managing Editor at Health-e News Service. Follow her on Twitter @kerrycullinan11
Republish this article
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Unless otherwise noted, you can republish our articles for free under a Creative Commons license. Here’s what you need to know:
You have to credit Health-e News. In the byline, we prefer “Author Name, Publication.” At the top of the text of your story, include a line that reads: “This story was originally published by Health-e News.” You must link the word “Health-e News” to the original URL of the story.
You must include all of the links from our story, including our newsletter sign up link.
If you use canonical metadata, please use the Health-e News URL. For more information about canonical metadata, click here.
You can’t edit our material, except to reflect relative changes in time, location and editorial style. (For example, “yesterday” can be changed to “last week”)
You have no rights to sell, license, syndicate, or otherwise represent yourself as the authorized owner of our material to any third parties. This means that you cannot actively publish or submit our work for syndication to third party platforms or apps like Apple News or Google News. Health-e News understands that publishers cannot fully control when certain third parties automatically summarise or crawl content from publishers’ own sites.
You can’t republish our material wholesale, or automatically; you need to select stories to be republished individually.
If you share republished stories on social media, we’d appreciate being tagged in your posts. You can find us on Twitter @HealthENews, Instagram @healthenews, and Facebook Health-e News Service.
You can grab HTML code for our stories easily. Click on the Creative Commons logo on our stories. You’ll find it with the other share buttons.
If you have any other questions, contact info@health-e.org.za.
Government: unconvinced about safety & efficacy of Nevirapine
by Kerry Cullinan, Health-e News
November 22, 2001